NO20020779D0 - Methods, preparations and kits to promote healing of central nervous system damage - Google Patents

Methods, preparations and kits to promote healing of central nervous system damage

Info

Publication number
NO20020779D0
NO20020779D0 NO20020779A NO20020779A NO20020779D0 NO 20020779 D0 NO20020779 D0 NO 20020779D0 NO 20020779 A NO20020779 A NO 20020779A NO 20020779 A NO20020779 A NO 20020779A NO 20020779 D0 NO20020779 D0 NO 20020779D0
Authority
NO
Norway
Prior art keywords
kits
preparations
methods
nervous system
central nervous
Prior art date
Application number
NO20020779A
Other languages
Norwegian (no)
Other versions
NO20020779L (en
Inventor
Seth P Finkelstein
Evan P Snyder
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Publication of NO20020779D0 publication Critical patent/NO20020779D0/en
Publication of NO20020779L publication Critical patent/NO20020779L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20020779A 1999-08-18 2002-02-15 Methods, preparations and kits to promote healing of central nervous system damage NO20020779L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14956199P 1999-08-18 1999-08-18
PCT/US2000/022843 WO2001012236A2 (en) 1999-08-18 2000-08-18 Methods, compositions and kits for promoting recovery from damage to the central nervous system

Publications (2)

Publication Number Publication Date
NO20020779D0 true NO20020779D0 (en) 2002-02-15
NO20020779L NO20020779L (en) 2002-04-15

Family

ID=22530841

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020779A NO20020779L (en) 1999-08-18 2002-02-15 Methods, preparations and kits to promote healing of central nervous system damage

Country Status (10)

Country Link
EP (1) EP1210106A2 (en)
JP (1) JP2003507349A (en)
CN (1) CN1753686A (en)
AU (1) AU6790300A (en)
BR (1) BR0013388A (en)
CA (1) CA2380953A1 (en)
IL (1) IL148175A0 (en)
MX (1) MXPA02001719A (en)
NO (1) NO20020779L (en)
WO (1) WO2001012236A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0021668D0 (en) * 2000-09-04 2000-10-18 Smithkline Beecham Plc New use
DE10111486A1 (en) * 2001-03-09 2002-10-02 Ralph R Dawirs Use of one or more neuroactive substances for the treatment of Parkinson's disease
GB0117645D0 (en) 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
US7981863B2 (en) * 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
WO2003059276A2 (en) * 2002-01-14 2003-07-24 The Board Of Trustees Of The University Of Illinois Novel mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof
CA2480423C (en) * 2002-04-08 2012-01-03 The Scripps Research Institute Truncated 24 kda basic fibroblast growth factor
US7153256B2 (en) 2003-03-07 2006-12-26 Neuronetics, Inc. Reducing discomfort caused by electrical stimulation
US8118722B2 (en) 2003-03-07 2012-02-21 Neuronetics, Inc. Reducing discomfort caused by electrical stimulation
DE10361596A1 (en) 2003-12-24 2005-09-29 Grünenthal GmbH Process for producing an anti-abuse dosage form
US8093205B2 (en) 2003-12-01 2012-01-10 Medtronic, Inc. Method for treating a stroke by implanting a first therapy delivery element in the CNS and a second therapy delivery element in a damaged tissue of the CNS to promote neurogenesis
US7651459B2 (en) 2004-01-06 2010-01-26 Neuronetics, Inc. Method and apparatus for coil positioning for TMS studies
US8177702B2 (en) 2004-04-15 2012-05-15 Neuronetics, Inc. Method and apparatus for determining the proximity of a TMS coil to a subject's head
US7601115B2 (en) 2004-05-24 2009-10-13 Neuronetics, Inc. Seizure therapy method and apparatus
US20060104969A1 (en) * 2004-08-16 2006-05-18 Massachusetts Institute Of Technology Compositions and methods for enhancing structural and functional nervous system reorganization and recovery
US7857746B2 (en) 2004-10-29 2010-12-28 Nueronetics, Inc. System and method to reduce discomfort using nerve stimulation
US8088058B2 (en) 2005-01-20 2012-01-03 Neuronetics, Inc. Articulating arm
US7396326B2 (en) 2005-05-17 2008-07-08 Neuronetics, Inc. Ferrofluidic cooling and acoustical noise reduction in magnetic stimulators
US7824324B2 (en) 2005-07-27 2010-11-02 Neuronetics, Inc. Magnetic core for medical procedures
US20070135859A1 (en) * 2005-12-09 2007-06-14 Peter Eriksson Use of transcranial magnetic stimulation to improve memory and stress related syndromes in humans
KR101467136B1 (en) * 2006-06-02 2014-12-01 화이자 프로덕츠 인코포레이티드 Circulating tumor cell assay
DE102007003565B4 (en) 2007-01-24 2012-05-24 Forschungszentrum Jülich GmbH Device for reducing the synchronization of neuronal brain activity and suitable coil
US9884200B2 (en) 2008-03-10 2018-02-06 Neuronetics, Inc. Apparatus for coil positioning for TMS studies
WO2010033576A1 (en) 2008-09-16 2010-03-25 University Of Central Florida Research Foundation, Inc. Compositions for treating or delaying the onset of hair loss
AU2012225784B2 (en) * 2011-03-04 2016-03-17 The Regents Of The University Of California Locally released growth factors to mediate motor recovery after stroke
WO2013067770A1 (en) * 2011-11-10 2013-05-16 Jinhui Chen Compositions and methods for treating traumatic brain injury
CN103421800B (en) * 2013-09-05 2015-07-22 新乡医学院 Recombinant gene, recombinant carrier and recombinant cell for treating spinal cord injuries
CN103555747B (en) * 2013-10-22 2015-04-08 深圳先进技术研究院 Gliocyte bFGF expression enhancement system, as well as construction method and application thereof
SG11201700971XA (en) * 2014-08-15 2017-03-30 Nat Health Research Institutes Methods to enhance nerve regeneration utilizing neural stem cells and il12p40

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612211A (en) * 1990-06-08 1997-03-18 New York University Stimulation, production and culturing of hematopoietic progenitor cells by fibroblast growth factors
US5750376A (en) * 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
US5981165A (en) * 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. In vitro induction of dopaminergic cells
WO1994003199A1 (en) * 1992-08-04 1994-02-17 Regeneron Pharmaceuticals, Inc. Method of enhancing differentiation and survival of neuronal precursor cells
CN1122716C (en) * 1994-03-07 2003-10-01 依默耐克斯有限公司 Extracorporeal ceel culture and transplantation kits
DE69723429T3 (en) * 1996-03-22 2007-09-20 Curis, Inc., Cambridge Method for improved functional recovery of motor coordination, speech or sensory perception after trauma or ischemia of the CNS
US20020136705A1 (en) * 1998-06-30 2002-09-26 Jonathan Dinsmore Porcine spinal cord cells and their use in spinal cord repair
ES2531592T3 (en) * 1999-05-14 2015-03-17 Henry Ford Health System Bone marrow transplant for stroke treatment

Also Published As

Publication number Publication date
CA2380953A1 (en) 2001-02-22
WO2001012236A2 (en) 2001-02-22
EP1210106A2 (en) 2002-06-05
WO2001012236A3 (en) 2001-08-30
AU6790300A (en) 2001-03-13
NO20020779L (en) 2002-04-15
IL148175A0 (en) 2002-09-12
BR0013388A (en) 2002-08-27
MXPA02001719A (en) 2003-09-25
JP2003507349A (en) 2003-02-25
CN1753686A (en) 2006-03-29
WO2001012236A9 (en) 2002-09-06

Similar Documents

Publication Publication Date Title
NO20020779L (en) Methods, preparations and kits to promote healing of central nervous system damage
NO20024577D0 (en) Method of treatment using ligand-immunogenic conjugates
DK1076657T3 (en) New hydroxy indoles, their use as inhibitors of phosphodiesterase 4 and process for their preparation
NO20016114L (en) Preparations and Methods to Increase Cholesterol Elevation and Raise HDL Using ATP Binding Cartridge Carrier Protein ABC1
AU1449401A (en) Method using prior activities to improve the completion of transaction
NO20031218L (en) Combination therapy for the treatment of autoimmune diseases using B-cell-reducing immunoregulatory antibody combination
NO20002796L (en) Combined process for improved hydrogen treatment of diesel fuels
NO20001870L (en) New procedure for treatment
AU2000260550A1 (en) Treatment of skin damage using polyenylphosphatidylcholine
AU1811301A (en) Methods for removal, purification, and concentration of viruses, and methods of therapy based thereupon
EA200000274A3 (en) METHODS OF OBTAINING AND INTERMEDIATE CONNECTIONS FOR OBTAINING ANTI-TRAY COMPOUNDS
ID30276A (en) METHODS FOR TREATING SEXUAL DISORDERS
AU2002360544A1 (en) Methods and system for adding liquidity to alternative investment transactions
NO20013770D0 (en) Methods and compositions to increase the number of white blood cells
ATE269303T1 (en) ARYLPIPERAZINYL-CYCLOHEXYL INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION
AU3998400A (en) Methods of treating c1s-mediated diseases and conditions, and compounds and compositions therefor
IS6575A (en) Hydroxyphenyl-piperidin-4-ylidene-methyl-benzamide derivatives to treat pain
AU2002210462A1 (en) Transdermal therapeutic system for treating restless-legs-syndrome
NO20026222L (en) Method of treating neutrophil-related diseases with topical anesthetics
AUPQ877300A0 (en) Topical treatment of skin
AU2002249779A1 (en) Method to treat hemophilia
AU2001268233A1 (en) Compositions and methods for treating neoplastic disease using inhibitors of laminin5beta3
ID29792A (en) CONTROLLED REMOVAL FORMULATION TO TREAT CORP
IS6563A (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives to treat pain
NO20006117D0 (en) Aza heterocyclic compounds used to treat neurological diseases and hair loss

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application